Search

Background: Aging and frailty pose significant challenges globally, placing a substantial burden on healthcare and social services due to their adverse consequences. Aim: The primary objective of this study was to investigate the relationship between social participation and development of frailty transition and trajectory. Methods: This study utilized data from the CLHLS Cohort, a 10-year follow-up study involving 6713 participants, to investigate the association between social participation and development of frailty. Frailty reflects a comprehensive decline in various body functions. The study employed a group-based trajectory model to analyze the development trajectory of the frailty index and used logistic regression to assess the odds ratio (OR) of frailty risk. Results: We identified two distinct groups of frailty progression trajectories: the "stable development group" and the "rapid growth group." Individuals who engaged in social activities at least once a month, but not daily, exhibited a significant association with an increased risk of transitioning into the "rapid growth group" (OR 1.305, 95% CI 1.032–1.649). Those with social participation less than once a month had an even greater risk (OR 1.872, 95% CI 1.423–2.463). Moreover, low social participation frequency (occasionally/never) has a more pronounced impact on frailty progression in males. Conclusion: A higher frequency of social participation is associated with a lower risk of being classified into the "rapid growth group" and a slower rate of frailty index progression. Preventing the progression of frailty can contribute to enhanced support for healthy aging among older adults. [ABSTRACT FROM AUTHOR]

Purpose: With the escalating social pressures, there has been a continuous rise in the prevalence of depression among the population, leading to substantial healthcare burdens. Moreover, conventional pharmacological interventions still exhibit certain limitations. Therefore, the primary objective of this study is to systematically evaluate the clinical efficacy of probiotics in the treatment of depression. Methods: Randomized controlled trials of probiotics in treating depressive symptoms were retrieved from Pubmed, Cochrane Library, Web of Science, Wan Fang database, and CNKI between the establishment of the database and March 2022. The primary outcome was Beck's depression rating scale (BDI) scores, while the secondary outcomes were depression scores on the DASS-21 scale, biochemical indicators (IL-6, NO, and TNF-α levels), and adverse events. In addition, Revman 5.3 was used for Meta-analysis and quality evaluation, and Stata 17 was used for the Egger test and Begg's test. A total of 776 patients, including 397 and 379 patients in the experimental and control groups, respectively, were included. Results: The total BDI score of the experimental group was lower than that of the control group (MD = − 1.98, 95%CI − 3.14 to − 0.82), and the score of DASS (MD = 0.90, 95%CI − 1.17 to 2.98), the IL-6 level (SMD = − 0.55, 95%CI − 0.88 to − 0.23), the NO level (MD = 5.27, 95% CI 2.51 to 8.03), and the TNF-α level (SMD = 0.19, 95% CI − 0.25 to 0.63). Conclusion: The findings substantiate the therapeutic potential of probiotics in mitigating depressive symptoms by significantly reducing Beck's Depression Inventory (BDI) scores and alleviating the overall manifestation of depression. [ABSTRACT FROM AUTHOR]